Health · 1 views
Boosted Bacille Calmette-Guérin vaccine strategy significantly reduces tuberculosis relapse, scientists find
Tuberculosis (TB) remains one of the world's leading causes of death, and preventing post-treatment relapse continues to be a major global health challenge.
AI Summary
Scientists at the Hackensack Meridian Center for Discovery and Innovation tested a new strategy that pairs an immunotherapy with the standard Bacille Calmette‑Guérin (BCG) vaccine. In preclinical models, the combined approach markedly lowered the risk of tuberculosis relapse after treatment. The study highlights the potential of augmenting BCG with additional immune‑boosting agents to improve long‑term outcomes for TB patients.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Pennsylvania asks CDC for emergency help as measles outbreak spreadsContinue reading
- Using 'neurodivergent' as a catch‑all term is problematic—here's whyContinue reading
- 1 in 3 Americans with health insurance have medical debt, survey findsContinue reading
- Women experience less pain during IUD insertion using a new methodContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow